Calico Life Sciences LLC — the Google Inc.-backed aging research company led by former Genentech Inc. CEO Art Levinson — signed a research deal with the Buck Institute for Research on Aging that includes setting up shop at the institute's Novato complex.
Terms of the pact weren't disclosed, but it is the latest in a stable of relationships forged by South San Francisco-based Calico since its formation in summer 2013. The deals are designed to identify, fund and support basic research. However, the end game is for Calico to build a portfolio of potential therapies for age-related diseases that ultimately could include drugs to treat neurodegenerative conditions, cancer and more.
With the Buck Institute, Calico has the option to grab exclusive rights to discoveries made through research it supports. But it also will establish and maintain "certain science operations" at the Buck.
"We are excited to forge this new partnership with Calico, which represents a unique way for academic researchers focused on aging and the biotech industry to work together," Buck Institute President and CEO Brian Kennedy said in a press release Tuesday.
Asked about Calico taking space at the Buck, an institute spokeswoman declined to comment.
It isn't the first time the Buck has opened up buildings to an outsider. Cellular Dynamics International and the Coriell Institute for Medical Research have lab space and a repository at the Buck that houses a collection of induced pluripotent stem cell lines.